FDA advisors on Wednesday will deliberate on whether shunt therapy still has a narrow path forward in heart failure after a disappointing pivotal trial. In its premarket approval application for the ...
Doctors say that identifying the right patients will be critical to the future of the field. Only time will tell, according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results